Human papillomavirus genotype distribution among French women with and without cervical abnormalities

Science Direct

International Journal of Gynecology & Obstetrics
Volume 114, Issue 2, August 2011, Pages 116-119

Jean-Sebastien Casalegnoa, Mehdi Benchaibb, Karine Le Bail Carvalc, Eric Piatond, Patrice Mathevetc and Yahia Mekkia, low asterisk, E-mail The Corresponding Author

a Laboratory of Virology, Femme-Mère-Enfant Hospital, Bron, France

b Department of Reproductive Medicine, Femme-Mère-Enfant Hospital, Bron, France

c Department of Gynecology and Obstetrics, Femme-Mère-Enfant Hospital, Bron, France

d Department of Anatomopathology, Femme-Mère-Enfant Hospital, Bron, France

Received 27 October 2010;
revised 24 January 2011;
accepted 10 May 2011.
Available online 12 June 2011.



To assess human papillomavirus (HPV) prevalence and distribution among French women with normal and pathologic cytology findings.


A genomic DNA microarray assay enabling the detection of 35 different HPV genotypes was used for in vitro diagnosis, as a complement to Papanicolaou screening, to test 785 women who attended the gynecology department of a hospital in Lyon, France.


Pathologic and normal cytology findings were obtained for 260 (33.1%) and 302 (38.5%) of the 785 women, respectively, whereas 223 (28.4%) results were inconclusive. HPV infection and multiple infection were significantly more prevalent (P < 0.001) in the population with pathologic findings (90.0% and 41.9%, respectively) than in the population with normal cytology findings (48.3% and 20.2%, respectively). Overall, the 4 most frequent HPV genotypes were HPV-16 (14.8%), HPV-53 (9.0%), HPV-31 (8.7%), and HPV-51 (7.5%), whereas HPV-18 (3.8%), HPV-6 (2.9%), and HPV-11 (0.4%) were less common. The HPV genotypes included in the quadrivalent vaccination had a prevalence of 20.6% among all women and 30.4% among those with pathologic findings.


The present data indicate a reduced direct impact of HPV vaccination in the study population owing to a low prevalence of HPV-18 and a high prevalence of HPV-53, HPV-31, and HPV-51.

Keywords: Cervical cancer; Cervical dysplasia; HPV; HPV DNA microarray assay; HPV genotyping; HPV prevalence

Read More…


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.